{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T07:17:14Z","timestamp":1763968634752,"version":"3.41.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T00:00:00Z","timestamp":1748044800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-03004-9","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T12:07:10Z","timestamp":1748088430000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Integration of network pharmacology, transcriptomics, and experimental verification to investigate the mechanism of action of cepharanthine hydrochloride against prostate cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Zongming","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosa","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingting","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bishao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronghua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingzhen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,24]]},"reference":[{"key":"3004_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"3004_CR2","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3760\/cma.j.cn112152-20240119-00035","volume":"46","author":"RS Zheng","year":"2024","unstructured":"Zheng, R. S. et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi Chin. J. Oncol. 46, 221\u2013231. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20240119-00035 (2024).","journal-title":"Zhonghua Zhong Liu Za Zhi Chin. J. Oncol."},{"key":"3004_CR3","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.3390\/ijms25084171","volume":"25","author":"M Martin-Caraballo","year":"2024","unstructured":"Martin-Caraballo, M. Regulation of molecular biomarkers associated with the progression of prostate cancer. Int. J. Mol. Sci. 25, 4171. https:\/\/doi.org\/10.3390\/ijms25084171 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain, M. et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: A review. JAMA Oncol. 10, 807\u2013820. https:\/\/doi.org\/10.1001\/jamaoncol.2024.0591 (2024).","journal-title":"JAMA Oncol."},{"key":"3004_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He, Y. et al. Targeting signaling pathways in prostate cancer: Mechanisms and clinical trials. Signal Transduct. Target. Ther. 7, 198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"3004_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ijbiomac.2021.09.011","volume":"190","author":"BS Cavada","year":"2021","unstructured":"Cavada, B. S. et al. Lectins applied to diagnosis and treatment of prostate cancer and benign hyperplasia: A review. Int. J. Biol. Macromol. 190, 543\u2013553. https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.09.011 (2021).","journal-title":"Int. J. Biol. Macromol."},{"key":"3004_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.eururo.2020.06.020","volume":"78","author":"AH Bryce","year":"2020","unstructured":"Bryce, A. H., Sartor, O. & de Bono, J. DNA repair and prostate cancer: A field ripe for harvest. Eur. Urol. 78, 486\u2013488. https:\/\/doi.org\/10.1016\/j.eururo.2020.06.020 (2020).","journal-title":"Eur. Urol."},{"key":"3004_CR8","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","volume":"38","author":"P Sharma","year":"2020","unstructured":"Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: Preliminary analysis of patients in the checkmate 650 trial. Cancer Cell 38, 489-499.e483. https:\/\/doi.org\/10.1016\/j.ccell.2020.08.007 (2020).","journal-title":"Cancer Cell"},{"key":"3004_CR9","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.3390\/ijms25042152","volume":"25","author":"P Guerrero-Ochoa","year":"2024","unstructured":"Guerrero-Ochoa, P. et al. Prostate cancer and the mevalonate pathway. Int. J. Mol. Sci. 25, 2152. https:\/\/doi.org\/10.3390\/ijms25042152 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.jep.2014.04.024","volume":"154","author":"C Desgrouas","year":"2014","unstructured":"Desgrouas, C. et al. Ethnobotany, phytochemistry and pharmacology of Stephania rotunda Lour. J. Ethnopharmacol. 154, 537\u2013563. https:\/\/doi.org\/10.1016\/j.jep.2014.04.024 (2014).","journal-title":"J. Ethnopharmacol."},{"key":"3004_CR11","doi-asserted-by":"publisher","first-page":"11250","DOI":"10.3390\/ijms231911250","volume":"23","author":"Y Chen","year":"2022","unstructured":"Chen, Y. et al. Antiviral drugs screening for swine acute diarrhea syndrome coronavirus. Int. J. Mol. Sci. 23, 11250. https:\/\/doi.org\/10.3390\/ijms231911250 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/s1734-1140(11)70500-x","volume":"63","author":"M Rogosnitzky","year":"2011","unstructured":"Rogosnitzky, M. & Danks, R. Therapeutic potential of the biscoclaurine alkaloid, cepharanthine, for a range of clinical conditions. Pharmacol. Rep. PR 63, 337\u2013347. https:\/\/doi.org\/10.1016\/s1734-1140(11)70500-x (2011).","journal-title":"Pharmacol. Rep. PR"},{"key":"3004_CR13","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.lfs.2006.12.001","volume":"80","author":"S Furusawa","year":"2007","unstructured":"Furusawa, S. & Wu, J. The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci. 80, 1073\u20131079. https:\/\/doi.org\/10.1016\/j.lfs.2006.12.001 (2007).","journal-title":"Life Sci."},{"key":"3004_CR14","doi-asserted-by":"publisher","first-page":"5956526","DOI":"10.1155\/2022\/5956526","volume":"2022","author":"B Liu","year":"2022","unstructured":"Liu, B. & Deng, J. X. Effect of cepharanthine on the stemness of lung squamous cell carcinoma based on network pharmacology and bioinformatics. Biomed. Res. Int. 2022, 5956526. https:\/\/doi.org\/10.1155\/2022\/5956526 (2022).","journal-title":"Biomed. Res. Int."},{"key":"3004_CR15","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.3390\/ijms19103280","volume":"19","author":"SA Shahriyar","year":"2018","unstructured":"Shahriyar, S. A., Woo, S. M., Seo, S. U., Min, K. J. & Kwon, T. K. Cepharanthine enhances TRAIL-mediated apoptosis through STAMBPL1-mediated downregulation of survivin expression in renal carcinoma cells. Int. J. Mol. Sci. 19, 3280. https:\/\/doi.org\/10.3390\/ijms19103280 (2018).","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/s0304-4165(98)00146-9","volume":"1426","author":"K Kogure","year":"1999","unstructured":"Kogure, K. et al. Potent antiperoxidation activity of the bisbenzylisoquinoline alkaloid cepharanthine: The amine moiety is responsible for its pH-dependent radical scavenge activity. Biochem. Biophys. Acta. 1426, 133\u2013142. https:\/\/doi.org\/10.1016\/s0304-4165(98)00146-9 (1999).","journal-title":"Biochem. Biophys. Acta."},{"key":"3004_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lfs.2016.06.002","volume":"157","author":"YA Samra","year":"2016","unstructured":"Samra, Y. A. et al. Cepharanthine and Piperine ameliorate diabetic nephropathy in rats: Role of NF-\u03baB and NLRP3 inflammasome. Life Sci. 157, 187\u2013199. https:\/\/doi.org\/10.1016\/j.lfs.2016.06.002 (2016).","journal-title":"Life Sci."},{"key":"3004_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/bib\/bbaa387","volume":"22","author":"S Li","year":"2021","unstructured":"Li, S. et al. Transcriptome analysis of cepharanthine against a SARS-CoV-2-related coronavirus. Brief. Bioinform. 22, 1378\u20131386. https:\/\/doi.org\/10.1093\/bib\/bbaa387 (2021).","journal-title":"Brief. Bioinform."},{"key":"3004_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41422-021-00581-y","volume":"32","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. Comparison of viral RNA-host protein interactomes across pathogenic RNA viruses informs rapid antiviral drug discovery for SARS-CoV-2. Cell Res. 32, 9\u201323. https:\/\/doi.org\/10.1038\/s41422-021-00581-y (2022).","journal-title":"Cell Res."},{"key":"3004_CR20","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.febslet.2005.12.048","volume":"580","author":"KK Biswas","year":"2006","unstructured":"Biswas, K. K. et al. Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1\/2 and the downregulation of Akt. FEBS Lett. 580, 703\u2013710. https:\/\/doi.org\/10.1016\/j.febslet.2005.12.048 (2006).","journal-title":"FEBS Lett."},{"key":"3004_CR21","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3892\/or.2017.6084","volume":"39","author":"A Rattanawong","year":"2018","unstructured":"Rattanawong, A. et al. Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1\/Cip1. Oncol. Rep. 39, 227\u2013238. https:\/\/doi.org\/10.3892\/or.2017.6084 (2018).","journal-title":"Oncol. Rep."},{"key":"3004_CR22","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1159\/000471234","volume":"41","author":"S Gao","year":"2017","unstructured":"Gao, S., Li, X., Ding, X., Qi, W. & Yang, Q. Cepharanthine induces autophagy, apoptosis and cell cycle arrest in breast cancer cells. Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 41, 1633\u20131648. https:\/\/doi.org\/10.1159\/000471234 (2017).","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"3004_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2019.108726","volume":"310","author":"W Xu","year":"2019","unstructured":"Xu, W. et al. Tetrandrine and cepharanthine induce apoptosis through caspase cascade regulation, cell cycle arrest, MAPK activation and PI3K\/Akt\/mTOR signal modification in glucocorticoid resistant human leukemia Jurkat T cells. Chem. Biol. Interact. 310, 108726. https:\/\/doi.org\/10.1016\/j.cbi.2019.108726 (2019).","journal-title":"Chem. Biol. Interact."},{"issue":"D1","key":"3004_CR24","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe, M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51(D1), D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"3004_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.127429","volume":"253","author":"X Liu","year":"2023","unstructured":"Liu, X., Cui, S., Li, W., Xie, H. & Shi, L. Elucidation of the anti-colon cancer mechanism of Phellinus baumii polyphenol by an integrative approach of network pharmacology and experimental verification. Int. J. Biol. Macromol. 253, 127430. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.127429 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"3004_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/bs.apha.2024.04.001","volume":"100","author":"L Grogan","year":"2024","unstructured":"Grogan, L. & Shapiro, P. Progress in the development of ERK1\/2 inhibitors for treating cancer and other diseases. Adv. Pharmacol (San Diego, Calif.) 100, 181\u2013207. https:\/\/doi.org\/10.1016\/bs.apha.2024.04.001 (2024).","journal-title":"Adv. Pharmacol (San Diego, Calif.)"},{"key":"3004_CR27","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.3390\/ijms20051194","volume":"20","author":"G Maik-Rachline","year":"2019","unstructured":"Maik-Rachline, G., Hacohen-Lev-Ran, A. & Seger, R. Nuclear ERK: Mechanism of translocation, substrates, and role in cancer. Int. J. Mol. Sci. 20, 1194. https:\/\/doi.org\/10.3390\/ijms20051194 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR28","doi-asserted-by":"publisher","first-page":"13561","DOI":"10.1021\/acs.jmedchem.2c01244","volume":"65","author":"L Fu","year":"2022","unstructured":"Fu, L., Chen, S., He, G., Chen, Y. & Liu, B. Targeting extracellular signal-regulated protein kinase 1\/2 (ERK1\/2) in cancer: An update on pharmacological small-molecule inhibitors. J. Med. Chem. 65, 13561\u201313573. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01244 (2022).","journal-title":"J. Med. Chem."},{"key":"3004_CR29","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"3004_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrurol.2018.9","volume":"15","author":"T Jamaspishvili","year":"2018","unstructured":"Jamaspishvili, T. et al. Clinical implications of PTEN loss in prostate cancer. Nat. Rev. Urol. 15, 222\u2013234. https:\/\/doi.org\/10.1038\/nrurol.2018.9 (2018).","journal-title":"Nat. Rev. Urol."},{"key":"3004_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/35065000","volume":"410","author":"L Chang","year":"2001","unstructured":"Chang, L. & Karin, M. Mammalian MAP kinase signalling cascades. Nature 410, 37\u201340. https:\/\/doi.org\/10.1038\/35065000 (2001).","journal-title":"Nature"},{"key":"3004_CR32","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41580-020-0255-7","volume":"21","author":"H Lavoie","year":"2020","unstructured":"Lavoie, H., Gagnon, J. & Therrien, M. ERK signalling: A master regulator of cell behaviour, life and fate. Nat. Rev. Mol. Cell Biol. 21, 607\u2013632. https:\/\/doi.org\/10.1038\/s41580-020-0255-7 (2020).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"3004_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/leu.2010.323","volume":"25","author":"M Masiero","year":"2011","unstructured":"Masiero, M. et al. Notch3-mediated regulation of MKP-1 levels promotes survival of T acute lymphoblastic leukemia cells. Leukemia 25, 588\u2013598. https:\/\/doi.org\/10.1038\/leu.2010.323 (2011).","journal-title":"Leukemia"},{"key":"3004_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2021.110033","volume":"84","author":"M Mutlak","year":"2021","unstructured":"Mutlak, M. & Kehat, I. Dual specific phosphatases (DUSPs) in cardiac hypertrophy and failure. Cell. Signal. 84, 110033. https:\/\/doi.org\/10.1016\/j.cellsig.2021.110033 (2021).","journal-title":"Cell. Signal."},{"key":"3004_CR35","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.3390\/ijms20184372","volume":"20","author":"R Pulido","year":"2019","unstructured":"Pulido, R. & Lang, R. Dual specificity phosphatases: From molecular mechanisms to biological function. Int. J. Mol. Sci. 20, 4372. https:\/\/doi.org\/10.3390\/ijms20184372 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"3004_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125867","volume":"248","author":"H Dang","year":"2023","unstructured":"Dang, H. et al. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK\/ERK and PI3K\/AKT pathways. Int. J. Biol. Macromol. 248, 125867. https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.125867 (2023).","journal-title":"Int. J. Biol. Macromol."},{"key":"3004_CR37","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.yexcr.2005.06.022","volume":"309","author":"C Liu","year":"2005","unstructured":"Liu, C. et al. Dual-specificity phosphatase DUSP1 protects overactivation of hypoxia-inducible factor 1 through inactivating ERK MAPK. Exp. Cell Res. 309, 410\u2013418. https:\/\/doi.org\/10.1016\/j.yexcr.2005.06.022 (2005).","journal-title":"Exp. Cell Res."},{"key":"3004_CR38","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/sj.onc.1209899","volume":"26","author":"W Yu","year":"2007","unstructured":"Yu, W. et al. A novel amplification target, DUSP26, promotes anaplastic thyroid cancer cell growth by inhibiting p38 MAPK activity. Oncogene 26, 1178\u20131187. https:\/\/doi.org\/10.1038\/sj.onc.1209899 (2007).","journal-title":"Oncogene"},{"key":"3004_CR39","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/nm.2795","volume":"18","author":"JM Balko","year":"2012","unstructured":"Balko, J. M. et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18, 1052\u20131059. https:\/\/doi.org\/10.1038\/nm.2795 (2012).","journal-title":"Nat. Med."},{"key":"3004_CR40","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/onc.2010.449","volume":"30","author":"V Moncho-Amor","year":"2011","unstructured":"Moncho-Amor, V. et al. DUSP1\/MKP1 promotes angiogenesis, invasion and metastasis in non-small-cell lung cancer. Oncogene 30, 668\u2013678. https:\/\/doi.org\/10.1038\/onc.2010.449 (2011).","journal-title":"Oncogene"},{"key":"3004_CR41","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1007\/s00268-012-1608-y","volume":"36","author":"MF Hou","year":"2012","unstructured":"Hou, M. F. et al. Decreased total MKP-1 protein levels predict poor prognosis in breast cancer. World J. Surg. 36, 1922\u20131932. https:\/\/doi.org\/10.1007\/s00268-012-1608-y (2012).","journal-title":"World J. Surg."},{"key":"3004_CR42","doi-asserted-by":"publisher","first-page":"1536375","DOI":"10.3389\/fphar.2025.1536375","volume":"16","author":"JS Guan","year":"2025","unstructured":"Guan, J. S. et al. Cepharanthine hydrochloride: A novel ferroptosis-inducing agent for prostate cancer treatment. Front. Pharmacol. 16, 1536375. https:\/\/doi.org\/10.3389\/fphar.2025.1536375 (2025).","journal-title":"Front. Pharmacol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03004-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03004-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T12:07:12Z","timestamp":1748088432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03004-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3004"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03004-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,24]]},"assertion":[{"value":"18 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18115"}}